key: cord-0715612-gaimvjbp
authors: Zhou, Tongqing; Teng, I-Ting; Olia, Adam S.; Cerutti, Gabriele; Gorman, Jason; Nazzari, Alexandra; Shi, Wei; Tsybovsky, Yaroslav; Wang, Lingshu; Wang, Shuishu; Zhang, Baoshan; Zhang, Yi; Katsamba, Phinikoula S.; Petrova, Yuliya; Banach, Bailey B.; Fahad, Ahmed S.; Liu, Lihong; Lopez Acevedo, Sheila N.; Madan, Bharat; Oliveira de Souza, Matheus; Pan, Xiaoli; Wang, Pengfei; Wolfe, Jacy R.; Yin, Michael; Ho, David D.; Phung, Emily; DiPiazza, Anthony; Chang, Lauren; Abiona, Olubukola M.; Corbett, Kizzmekia S.; DeKosky, Brandon J.; Graham, Barney S.; Mascola, John R.; Misasi, John; Ruckwardt, Tracy; Sullivan, Nancy J.; Shapiro, Lawrence; Kwong, Peter D.
title: Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes
date: 2020-10-12
journal: Cell Rep
DOI: 10.1016/j.celrep.2020.108322
sha: 17fb523304e9ba97a8414384957950204b3634d8
doc_id: 715612
cord_uid: gaimvjbp

Biotin-labeled molecular probes, comprising specific regions of the SARS-CoV-2 spike, would be helpful in the isolation and characterization of antibodies targeting this recently emerged pathogen. Here, we design constructs incorporating an N-terminal purification tag, a site-specific protease-cleavage site, the probe region of interest, and a C-terminal sequence targeted by biotin ligase. Probe regions include full-length spike ectodomain as well as various subregions, and we also design mutants that eliminate recognition of the ACE2 receptor. Yields of biotin-labeled probes from transient transfection range from ∼0.5 mg/L for the complete ectodomain to >5 mg/L for several subregions. Probes are characterized for antigenicity and ACE2 recognition, and the structure of the spike ectodomain probe is determined by cryo-electron microscopy. We also characterize antibody-binding specificities and cell-sorting capabilities of the biotinylated probes. Altogether, structure-based design coupled to efficient purification and biotinylation processes can thus enable streamlined development of SARS-CoV-2 spike-ectodomain probes.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for Coronavirus Disease 2019 , emerged in 2019 and rapidly spread, infecting millions, overwhelming health-care systems, and impacting economies worldwide Cucinotta and Vanelli, 2020) . To respond, a global effort has been initiated to develop vaccines and therapeutic agents. For COVID-19 vaccine development (reviewed in Callaway, 2020) , the trimeric SARS-CoV-2 spike -a type 1 fusion machine that facilitates virus-cell entry through interaction with the ACE2 receptor (Hoffmann et al., 2020; Ou et al., 2020) -is a lead target, as antibodies against it can block virus entry . Most of the SARS-CoV-2 neutralizing antibodies so far isolated target the receptor binding domain (RBD) of the spike protein (Brouwer et al., 2020; Cao et al., 2020; Chen et al., 2020; Chi et al., 2020; Ju et al., 2020; Liu et al., 2020b; Pinto et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Wang et al., 2020a; Wrapp et al., 2020a; Zeng et al., 2020; Zost et al., 2020) , but there are other sites in the N-terminal domain and S2 stem domain that have also been associated with neutralizing activity against other betacoronaviruses (Pallesen et al., 2017; Wang et al., 2018b) . Such virus-neutralizing antibodies are sought as therapeutic and prophylactic agents (Cao et al., 2020; reviewed in Graham et al., 2013; Zhou and Zhao, 2020) .

Biotin-labeled molecular probes, comprising the SARS-CoV-2 spike as well as its discrete domains, can accelerate development of both vaccines and therapeutic antibodies. For vaccine development, such probes can be used to track humoral responses longitudinally (Liu et al., 2011; Yongchen et al., 2020) and to quantify elicited responses against spike and its domains, as correlating such responses with neutralization should provide crucial insight into sites of spike vulnerability. For antibody identification, probes are used in B cell sorting to identify B cells J o u r n a l P r e -p r o o f encoding antibodies capable of recognizing the spike or particular spike domains as well as characterization of antibody binding affinities through surface plasmon resonance (SPR) or biolayer interferometry (BLI) analyses.

Here we describe the structure-based design of molecular probes, encompassing SARS-CoV-2 spike and its domains. We first designed a construct that allowed for tag-based purification and on-column biotinylation. Next, we incorporated the SARS-CoV-2 spike ectodomain, with prefusion stabilizing mutations and a C-terminal trimerization motif, which we expressed, biotinylated, purified, and characterized, including by cryo-EM. Based on the structure-defined spike-domain organization Wrapp et al., 2020b) , we also created and characterized separate molecular probes comprising the N-terminal domain (NTD), the receptor-binding domain (RBD), and RBD with spike domain 1 (RBD-SD1). We also used the structure of RBD with ACE2 (Lan et al., 2020; Wang et al., 2020b; Yan et al., 2020a) to define mutations that could inhibit ACE2 interaction, which we incorporated into mutant RBD probes with ACE2-recognition ablated. Finally, we characterized properties of the devised probes including degree of biotinylation, antibody-binding specificity, and use in sorting yeast cells expressing SARS-CoV-2 spike-binding antibodies or B cells from a COVID-19 convalescent donor. Overall, our findings demonstrate how structure-based design can be used to develop molecular probes of the SARS-CoV-2 spike.

To facilitate purification and biotinylation, we devised a probe construct using the constant portion of an antibody (Fc) as an N-terminal purification tag. Fc expresses and folds J o u r n a l P r e -p r o o f efficiently and can be effectively captured by protein A resins (Jager et al., 2013) . To prevent intermolecular dimer formation of the Fc-tag, we used a single chain-Fc (scFc) with 'knob-inhole' feature (Ridgway et al., 1996) , in which a "knob" comprising a protruding tyrosine (T366Y) was incorporated into the N-terminal-half of the Fc-interface, followed by a 20-residuelinker (GGGGS) 4 and a "hole" comprising a recessed threonine (Y407T) was incorporated into the C-terminal-half Fc-interface [Kabat antibody residue numbering (Johnson and Wu, 2000) ] ( Figure 1A ).

Between the scFc and the target region of interest ( Figure 1A ), we added a cleavage site for the human rhinovirus 3C (HRV3C) protease (Cordingley et al., 1990) , a highly specific protease that recognizes the sequence LEVLFQGP, cleaving after Q and leaving a GP dipeptide at the start of the target. This allowed us to remove the target protein from the protein A-capture resin by protease treatment, avoiding low pH elution that is known to alter the conformations of type 1 fusion machine and could potentially alter the conformation of the probe. After the target sequence of interest, we incorporated a 10-residue linker followed by a biotin ligase-specific sequence (10lnQQ-AVI). This construct design enabled capture by protein A and on-column biotinylation ( Figure 1B ). As buffers for biotinylation and HRV3C cleavage are compatible, the entire process of biotinylation, HRV3C cleavage, and purification could in principle be accomplished with a single column, though we have generally added a polishing size exclusion chromatography step to ensure size homogeneity.

To obtain a molecular probe of the SARS-CoV-2 spike, we incorporated stabilizing mutations into the spike target protein residues 14 to 1208 (Wrapp et al., 2020b) , replacing J o u r n a l P r e -p r o o f RRAR at the S1/S2 cleavage site with GSAS and KV between domains HR1 and CH with PP ( Figure 2 and Table S1 ) and adding the T4-phage fibritin trimerization domain (foldon) at the Cterminus (Efimov et al., 1994; Miroshnikov et al., 1998 ) (this construct is hereafter referred to as S2P), and expressed it by transient mammalian cell transfection. We observed cleavage by HRV3C protease to be impeded with the glutathione-S-transferase-tagged, but not the His-tagged version of the protease, suggesting partial steric constraints on access to the HRV3C site; overall we could obtain ~0.5 mg of the purified S2P probe per liter cell culture after 24 h incubation at 4 °C with the His-tagged HRV3C.

The protease-liberated probe SARS-CoV-2 S2P ran primarily as a single peak on sizeexclusion chromatography and a major band on SDS-PAGE ( Figure 3A , B), appeared homogeneous by negative-stain EM ( Figure 3C ), and was recognized by the RBD-binding antibody CR3022 (Tian et al., 2020; Yuan et al., 2020) . We characterized binding to three antibodies from a SARS-CoV convalescent donor S652: S652-109, which recognizes the RBD, S652-112, which recognizes an epitope in S2, and S652-118, which recognizes the NTD. All three of these antibodies bound well to the S2P probe, as did the ACE2 receptor, but not to soluble CD4 (D1D2-sCD4) or antibody VRC01 (Wu et al., 2010) , which bound a control probe encompassing HIV-1 envelope glycoprotein trimer BG505 DS-SOSIP ( Figure 3D ). We further characterized binding to four antibodies recently isolated from SARS-CoV-2 convalescent donors: Antibodies 2-4 (Liu et al., 2020a) and B38 , which recognize the RBD, and 4-8 (Liu et al., 2020a) , which recognizes the NTD, and 2-51 (Liu et al., 2020a) , which clusters with other NTD-directed antibodies. All of these antibodies showed positive binding to the S2P probe ( Figure 3D ). All of these properties suggested the SARS-CoV-2 S2P probe to be a good biological mimic of the prefusion SARS-CoV-2 spike ectodomain.

J o u r n a l P r e -p r o o f

To provide atomic-level insight into the mimicry of spike by probe, we determined the cryo-EM structure of the biotinylated SARS-CoV-2 S2P probe ( Figures 3E and S3 ; Table S2 ).

The cryo-EM grids were frozen with the biotinylated SARS-CoV-2 S2P probe in PBS at pH 7.4.

We observed two distinct conformations, one with all three RBDs in the "down" position, displaying C3 symmetry, and the other with one RBD in the "up" position and the other two RBDs in the "down" position, C1-symmetric. We observed more particles (43, 176) in the RBDs down conformation, which contributed to a 3.45 Å resolution map, whereas the single-RBD-up state (34,223 particles) 3D reconstruction achieved an overall resolution of 4.00 Å. The two final atomic models were very similar to published cryo-EM spike-ectodomain structures Wrapp et al., 2020b) . The C1-symmetric structure included residues 27-1147, while residues 27-1152 were modeled for the C3-symmetric structure; in both cases some regions could not be modeled because of their intrinsic flexibility. Five additional residues at the Cterminal region (1148-1152) were visible in the reconstruction density of the RBDs down structure, but -similar to published structures Wrapp et al., 2020b ) -the Cterminal region of the S2 domain (and in our case the rest of the probe) were not sufficiently ordered to be modeled. The two structures were similar except for the single RBD that was in the "up" position in the C1 symmetry structure. Excluding this single RBD, the RMSD was 0.95 Å between the two probe structures for 2738 aligned Cα atoms.

The domain structure of the SARS-CoV-2 spike was clearly evident in our cryo-EM structure and consistent with published accounts Wrapp et al., 2020b) . Based on these structures, we created constructs incorporating NTD, RBD and RBD-SD1 regions as separate molecular probes ( Figure 4 ). Transient transfection yield for each of these constructs was greater than 5 mg/L. Both NTD and RBD eluted as a single peak on size-exclusion chromatography and exhibited a single band on SDS-PAGE ( Figure 5A , B). RBD-SD1 eluted as two peaks on SEC, a disulfide-bonded dimer and a monomer ( Figure 5A , B). We chose the monomeric form for further studies, as there is no biological basis for a higher association.

Receptor recognition of these domain probes was specific for each construct, with ACE2 binding to RBD and RBD-SD1 probes, but not the NTD probe ( Figure 5C ). Similarly, SARS-CoV antibodies CR3022 and S652-109 recognized RBD and RBD-SD1, while the S652-112 showed no binding to these two probes ( Figure 5D ); and antibody S652-118 recognized only the NTD probe ( Figure 5D ). Binding assays with SARS-CoV-2 antibodies further confirmed antigenic specificities of these domain probes ( Figure 5E ). Notably, the 2-51 antibody did recognize the NTD probe, consistent with its clustering but not in its reported NTD recognition (Liu et al., 2020a) . Overall, these results indicate that the truncated domain probes folded properly and retained the native conformation as on the full-length S2P probe.

Structural information can define not only domain boundaries, but also biological interfaces. Based on the structure of the RBD domain with ACE2 (Lan et al., 2020) (Figure 6A ), we designed constructs with ACE2-interface residues mutated to Arg to knockout ACE2 affinity ( Figure 6B ). We expressed and purified two double-Arg mutants (RBD-L455RA475R-AVI and J o u r n a l P r e -p r o o f RBD-L455RG496R-AVI) and one triple-Arg mutant (RBD-L455RA475RG502R-AVI). All three eluted in a single peak on size-exclusion chromatography and exhibited a single band on SDS-PAGE ( Figure 6C , D). All three mutants completely ablated ACE2 binding as designed ( Figure 6E ). By contrast, CR3022 recognition by all three mutants was mostly retained as the epitope of CR3022 and ACE2-binding site are located at different locations on RBD; S652-109 recognition by the double-Arg mutants was mostly retained and its recognition by RBD-L455RA475RG502R-AVI was reduced but at detectable level, indicating a potential epitope overlapping the G502 region ( Figure 6F ). SARS-CoV-2 antibody B38 binding to the RBD probes was abolished by the L455RA475R mutations while that to the RBD-L455RG496R-AVI probe was partially retained, indicating the critical role of the A475R mutation. In contrast, binding to 2-4 was reduced but not abolished ( Figure 6F ) by all mutations, consistent with the structural data that the epitope of 2-4 only partially overlaps with the ACE2-binding site (Liu et al., 2020a) . Our results indicated that the ACE2-interface-mutant probes can be used to specifically distinguish antibodies targeting the ACE2-binding site and other epitopes on the RBD.

To assess the molecular probes for their quality and function, we first performed kinetic analyses of ACE2 receptor and antibodies binding to the probes by SPR ( Figure 7A ). Purified biotinylated probes were immobilized on streptavidin sensor chip surface, and ACE2 and antibodies were in the mobile phase. ACE2 bound the full-length ectodomain probe S2P with a K D of 46.5 nM, and its affinity to the isolated RBD domain probe was somewhat lower with a K D of 121 nM. We found the S2P probe to be sensitive to chip regeneration required to remove J o u r n a l P r e -p r o o f antibody, so we used single-cycle kinetics to analyze the interaction with the Fabs of antibodies CR3022, S652-109, S652-112 and S652-118. These all bound SARS-CoV-2 S2P probe with high affinity ( Figure 7A , top row). Interestingly, the binding on-rates for all three of the antibodies were comparable, but the off-rates varied. CR3022, an antibody known to bind RBD but not neutralize the SARS-CoV-2 virus , bound to SARS-CoV-2 S2P at a lower affinity than ACE2 (91.4 vs 46.5 nM, respectively), although CR3022 had a higher affinity to the RBD probe (25.0 nM) than to S2P (91.4 nM). Another RBD-binding non-neutralizing antibody, S652-109, bound to the RBD and S2P probes at 1.63 and 3.96 nM, respectively. Antibody S652-112, also non-neutralizing, did not bind NTD or RBD probes ( Figure 5D ), but did bind S2P probe with a K D of 0.32 nM, consistent with it being S2 directed. An NTD-specific antibody, S652-118, which does have some neutralizing capacity, bound NTD and S2P probes at 1.74 and 1.46 nM, respectively. These results confirm that the biotinylated probes have the binding specificity for the receptor and antibodies and are functioning properly as expected.

We next tested the probes for sorting antigen-specific yeast cells displaying SARS-CoV- Overall, the designed probes were found to be functional in SPR and in sorting yeast cells or B cells with spike-reactive antibodies.

Molecular probes comprising key targets such as the SARS-CoV-2 spike and its domains can be of broad utility. For vaccine development, such probes can be used to define and monitor the elicited responses, and for antibody characterization, such probes can serve as critical J o u r n a l P r e -p r o o f molecular tags, facilitating the identification of the highly effective antibodies which could be used for passive therapy (Cao et al., 2020; reviewed in Casadevall et al., 2004; Graham and Ambrosino, 2015; Walker and Burton, 2018) . In diagnostics, they can be employed to assess sera reactivity and to provide sensitive markers of infection (Perera et al., 2020; Yan et al., 2020b; Zhao et al., 2020) . In pathogenesis, they can assist in delineating susceptible cells that virus might infect or in tracking viral variants, including those that might have selective advantages (Korber et al., 2020) . Here we show how structure-based design coupled to incorporation of (i) a purification-tag based construct, (ii) a sequence-specific protease, and (iii) a sequence-specific biotin ligase, enable streamlined probe development.

For probe construction, we used a process incorporating the 'cut-and-paste' assembly of necessary components, employing an N-terminal purification tag and sequence stretches targeted by sequence-specific enzymes: the HRV3C protease and biotin ligase. Other sequence-specific cleavage sites such as thrombin could be incorporated, to further control the presence of components surrounding the target protein of interest. Such protease-specific cleavage, however, can lead to the addition of residual amino acids at resultant N-and C-termini after protease cleavage; we note in this context that an N-terminal HRV3C site appends only a dipeptide, Gly-Pro, to the N-terminus of the liberated target. Importantly, structure of the target protein can define domain boundaries, allowing for separate probes of specific domains or domain combinations.

The structure-based methods we describe here for probe construction may allow for the assessment of immune responses of other type 1 fusion machines. We previously created hemagglutinin trimer probes with a Y96F mutation (Whittle et al., 2014) and used them to identify broadly neutralizing antibodies against influenza (Joyce et al., 2016) . We also created J o u r n a l P r e -p r o o f Ebolavirus trimer probes that could be used to identify protective neutralizing antibodies against Sudan outbreak Ebolavirus strain Gaudinski et al., 2019; Misasi et al., 2016) .

And we previously used a biotinylated envelope 'SOSIP' probe to identify broadly neutralizing, fusion peptide-directed antibodies against HIV-1 (Kong et al., 2016) . Overall, the cut-and-paste structure-based design described here should be easily adapted to the streamlined development of molecular probes against not only these pathogens, but also emerging pathogens, as shown here for SARS-CoV-2.

We thank R. Grassucci, Y.-C. Chi 

The authors declare no competing interest. See also Figures S1 and S3 and Tables S1 and S2. (B) SDS-PAGE of NTD, RBD and RBD-SD1 molecular probes. RBD-SD1 peak 1 appeared to be partially disulfide linked, and was therefore removed from further analysis; RBD-SD1 thus refers to the monomeric peak 2.

(C) Binding of receptor ACE2 to both RBD and RBD-SD1 probes. (E) Binding to receptor ACE2. All the knockout mutations abolished RBD binding to the ACE2 receptor.

(F) Binding to antibodies. Both SARS-CoV (top) and SARS-CoV-2 (bottom) antibodies were tested. Binding to all the SARS-CoV-2 antibodies and to SARS-CoV antibody S652-109 were reduced or abolished by the knockout mutations. Binding to CR3022, whose epitope is not on the ACE2-binding site, was not significantly affected. All binding was assessed using 7.5 µg/ml RBD-L455RA475R, 80µg/ml RBD-L455RG496R, or 15µg/ml RBD-L455RA475RG502R to account for varying biotinylation levels among the mutants. Receptor or antibodies were at 500 nM. HIV-1 antibody VRC01 was used as a negative control. Error bars represent standard deviation of triplicate measures. See also Figure S2 and Table S1. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by Peter D. Kwong (pdkwong@nih.gov).

Plasmids for the SARS-CoV-2 probes with AVI tag generated in this study have been deposited with Addgene (www.addgene.org) with accession numbers: 160474-160480. 

Expi293F and FreeStyle 293-F cells were purchased from Thermo Fisher Scientific. The cells were used directly from the commercial sources following manufacturer suggestions as described in detail below.

DNA sequences coding for the SARS-CoV-2 spike or its domains were cloned into a pVRC8400-based expression vector by GeneImmune. The gene of interest was placed after the DNA sequence encoding a N-terminus single chain human Fc with knob-in-hole mutations, a "GGSGGGGSGG" linker and an HRV3C protease cleavage site for purification with protein A column and on-column cleavage. DNA sequence encoding a C-terminus "GGGLVPQQSG" linker named10lnQQ and an AVI tag was placed after the gene of interest for biotinylation (Table S1 ).

For the scFc-SARS-CoV-2 S2P-AVI construct, the cloned insertion included the spike protein residues 14 to 1208 with GSAS replacing the RRAR at the S1/S2 cleavage site and K986P and V987P stabilization mutations, a GSG linker and the T4-phage fibritin trimerization J o u r n a l P r e -p r o o f domain (foldon) as described by Wrapp and colleagues (Wrapp et al., 2020b) . For the scFc-SARS-CoV-2 NTD-AVI construct, spike gene encoding residues 14-305 was cloned. For the scFc-SARS-CoV-2 RBD-AVI construct, spike gene encoding residues 329-526 was cloned. For the scFc-SARS-CoV-2 RBD-SD1-AVI construct, spike gene encoding residues 319-591 was cloned. The constructs comprising specific mutations for knocking out ACE2 interaction with RBD were made by site directed mutagenesis in the scFc=SARS-CoV-2-RBD-AVI plasmid, either in double Arg substitutions at L455 and A475 (L455RA475R), or at L455 and G496 (L455RG496R), or in triple Arg substitutions at L455, A475, and G502 (L455RA475RG502R).

A model of the 10lnQQ linker and AVI tag was obtained on the PEP-FOLD server (Shen et al., 2014; Thevenet et al., 2012) to show the location of this C-terminal addition in Figure S1 .

Single chain Fc tagged SARS-CoV-2 probes were produced by transient transfection of 293 Freestyle cells as previously described (Wrapp et al., 2020b) . One liter of cells was transfected with 1 mg of SARS-CoV-2 probe plasmid, pre-mixed with 3 ml of Turbo293 transfection reagent. The cells were allowed to grow for 6 days at 120 rpm, 37 °C, and 9 % CO 2 , after which the supernatant was harvested by centrifugation and filtered. The cleared supernatant was incubated with 5ml of PBS-equilibrated Protein A resin for two hours, after which the resin was then collected and washed with PBS. The captured SARS-CoV-2 probe was then concurrently biotinylated with 10-80 µg BirA enzyme (~2.5 µg per 10 nmol AVI substrate) and 100 µM biotin, as well as cleaved from the Fc purification tag with 200 µg of HRV3C, which was prepared as described (Antoniou et al., 2017) , in a reaction mixture containing 10 mM Tris Expression and preparation of antibodies DNA sequences of antibody heavy and light chain variable regions of antibody CR3022 and of donor S652 antibodies, S652-109, S652-112, and S652-118, and of SARS-CoV-2 antibodies B38 (Wu et al., 2020), 2-4, 4-8, and 2-51 (Liu et al., 2020a) were synthesized and subcloned into the pVRC8400 vector, as described previously (Wu et al., 2011) .

Antibody expression was carried out by co-transfection of both heavy and light chain plasmids in Expi293F cells (Thermo Fisher) using Turbo293 transfection reagent (Speed BioSystems). On day 6 post transfection, the culture supernatant was harvested and loaded on a protein A column.

After washing with PBS for 3 column volumes, IgG was eluted with an IgG elution buffer (Pierce) and immediately neutralized by addition of one tenth volume of 1M Tris-HCl pH 8.0.

A FortéBio Octet HTX instrument (FortéBio) was used to analyze biotinylation level, antigenicity, and receptor recognition of the molecular probes. Assays were performed at 30°C in tilted black 384-well plates (Geiger Bio-One) in PBS + 0.02% Tween20, 0.1% BSA, 0.05% sodium azide with agitation set to 1,000 rpm. Biotinylated SARS-CoV-2 spike (80 µg/ml), NTD Surface plasmon resonance SPR binding experiments were performed using a Biacore T200 biosensor, equipped with either a Series S SA chip for the Fab binding assays, or a Series S CM4 chip immobilized with NeutrAvidin, for the ACE2 binding assays. All measurements were performed at 25°C in a running buffer of 10 mM HEPES pH 7.4, 150 mM NaCl, and 0.05% (v/v) Tween-20.

Biotinylated spike, RBD, and NTD were captured over independent flow cells at 1000-1100 RU, 300-500 RU and 260 RU, respectively. ACE2-analyte samples were prepared in running buffer at a concentration range of 300-1.2nM using a three-fold dilution series. Binding over the spike and RBD or NTD surfaces as well as over a neutravidin reference surface was tested for 180s followed by a 300s dissociation phase at 50µL/min. Blank buffer cycles were performed throughout the experiment by injecting running buffer instead of ACE2 to subtract systematic noise from the binding signal. The data was processed and fit to 1:1 binding model using Scrubber 2.0 (BioLogic Software).

To avoid the need for surface regeneration that arises with the low off-rate Fabs, we used single-cycle kinetics for the Fab binding experiments. Each Fab was tested at analyte concentrations 180-6.66nM prepared in running buffer using a three-fold dilution series. Binding over the spike or RBD surface or the NTD surface for S652-118, was monitored for 120s, followed by a dissociation phase of 120s-900s depending on the interaction. Four blank buffer single cycles were performed by injecting running buffer instead of Fab to remove systematic noise from the binding signal. The data was processed and fit to 1:1 single cycle model using the Scrubber 2.0 (BioLogic Software).

Purified SARS-CoV-2 S samples were diluted to approximately 0.02 mg/ml with a buffer containing 10 mM HEPES, pH 7, and 150 mM NaCl. A 4.7-µl drop of the diluted sample was applied to a glow-discharged carbon-coated copper grid. The grid was washed with the same buffer, and adsorbed protein molecules were negatively stained with 0.75% uranyl formate.

Micrographs were collected at a nominal magnification of 100,000x (pixel size: 0.22 nm) using J o u r n a l P r e -p r o o f SerialEM (Mastronarde, 2005) on an FEI Tecnai T20 electron microscope operated at 200 kV and equipped with an Eagle CCD camera. Particles were picked automatically using in-house written software (Y.T., unpublished). Reference-free 2D classification was performed with Relion 1.4 (Scheres, 2012) .

Biotinylated SARS-CoV-2 spike probe was diluted to a final trimer concentration of 0.33 mg/mL in PBS, pH 7.4. The sample (2 µL) was applied to a glow-discharged carbon-coated copper grid (CF 1.2/1.3) and vitrified using a Vitrobot Mark IV with a wait time of 30 seconds and a blot time of 3 seconds.

Data were collected using the Leginon software (Suloway et al., 2005) installed on a Titan Krios electron microscope operating at 300 kV, equipped with a Gatan K3-BioQuantum direct detection device. The total dose was fractionated for 3 s over 60 raw frames. Motion correction, CTF estimation, particle picking and extraction, 2D classification, ab initio model generation, 3D refinements and local resolution estimation were carried out in cryoSPARC 2.14 (Punjani et al., 2017) . The 3D reconstructions were performed using C3 symmetry for the RBDs down map while C1 symmetry was applied for the 1 RBD up map. Local refinement (beta) with C1 symmetry was performed on the RBDs down map using a mask focused on the C-terminal helices, which included the bottom of the S2 subunit spanning from residue 1070 to the C terminus. The overall resolution was 3.45 Å for the RBDs down map, 4.00 Å for the 1 RBD up map, and 4.28 Å for the RBDs down local refinement map, confirmed by providing the half maps to Resolve Cryo EM in Phenix (Adams et al., 2004) .

The coordinates of SARS CoV-2 spike ectodomain structures, PDB entries 6VXX and 6VYB , were employed as initial models for fitting the cryo-EM map of the RBDs down and the 1 RBD up conformation respectively. In both structures, the RBDs in the "down" position were modeled using the crystallographic structure of RBD in complex with CR3022 Fab (PDB entry 6W41) as a template. For the RBD in the "up"

position the map quality did not allow visualization of most side chains which were then modeled as poly-Ala, consistent with what observed for 6VYB . Manual and automated model building were iteratively performed using Coot (Emsley and Cowtan, 2004) and real space refinement in Phenix respectively, in order to accurately fit the coordinates to the electron density map. Half maps were provided to Resolve Cryo EM tool in Phenix to support manual model building. EMRinger (Barad et al., 2015) and Molprobity (Davis et al., 2004) were used to validate geometry and check structure quality at each iteration step. UCSF Chimera (Pettersen et al., 2004) was used for map-fitting cross correlation calculation (Fit-in-Map tool) and for figure preparation.

Biotinylated SARS-CoV-2 spike probes were conjugated using either allophycocyanin Samples were collected on a BD FACS-ARIA III and analyzed with FlowJo v10.6.1.

The statistical analyses for the BLI assessment of probe-antibody binding were performed using GraphPad Prism. The SPR data were processed and fit to a 1:1 binding model using Scrubber 2.0 (BioLogic Software).

J o u r n a l P r e -p r o o f 

Recent developments in the PHENIX software for automated crystallographic structure determination

Optimization of Soluble Expression and Purification of Recombinant Human Rhinovirus Type-14 3C Protease Using Statistically Designed Experiments: Isolation and Characterization of the Enzyme

EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

The race for coronavirus vaccines: a graphical guide

The coronavirus pandemic in five powerful charts

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Passive antibody therapy for infectious diseases

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability

Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

WHO Declares COVID-19 a Pandemic

MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes

High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire

In-depth determination and analysis of the human paired heavy-and lightchain antibody repertoire

Fibritin encoded by bacteriophage T4 gene wac has a parallel triple-stranded alpha-helical coiled-coil structure

Coot: model-building tools for molecular graphics

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

History of passive antibody administration for prevention and treatment of infectious diseases

A decade after SARS: strategies for controlling emerging coronaviruses

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Kabat database and its applications: 30 years after the first variability plot

Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Ultrasonically-guided flow focusing generates precise emulsion droplets for high-throughput single cell analyses

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients

Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection

Automated electron microscope tomography using robust prediction of specimen movements

Engineering trimeric fibrous proteins based on bacteriophage T4 adhesins

Structural and molecular basis for Ebola virus neutralization by protective human antibodies

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune crossreactivity with SARS-CoV

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

UCSF Chimera--a visualization system for exploratory research and analysis

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination

Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

CTFFIND4: Fast and accurate defocus estimation from electron micrographs

RELION: implementation of a Bayesian approach to cryo-EM structure determination

Characterization of neutralizing antibodies from a SARS-CoV-2

Improved PEP-FOLD Approach for Peptide and Miniprotein Structure Prediction

Automated molecular microscopy: the new Leginon system

PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirusspecific human monoclonal antibody

DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy

Passive immunotherapy of viral infections: 'superantibodies' enter the fray

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Functional interrogation and mining of natively paired human VH:VL antibody repertoires

A human monoclonal antibody blocking SARS-CoV-2 infection

Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures

Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy

Gctf: Real-time CTF determination and correction

Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection

Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

On-column biotinylation and purification is enabled by affinity tag and HRV3C cleavage • Development of diverse molecular probes by 'cut-and-paste' strategy • Application of probes to SARS-CoV-2 antibody discovery and immune evaluation In Brief SARS-CoV-2 spike probes are key to antibody discovery and vaccine evaluation. By using structure-based design, affinity purification, on-column biotinylation and sequence-specific protease cleavage, Zhou et al. devise a strategy that allows for the rapid development of SARS-CoV-2 spike probes for B cell sorting

A SPR definition of ligand and antibody binding kinetics and affinity Response J o u r n a l P r e -p r o o f